52North Raises £3.2M for Cancer Sepsis Diagnostic

52North, a University of Cambridge spin-out, has successfully closed a £3.2 million funding round aimed at advancing its innovative diagnostic technology for cancer patients. The capital injection is set to accelerate the clinical validation and regulatory approval of its Neutrocheck system, a critical tool designed to identify the risk of neutropenic sepsis, a potentially fatal complication arising from chemotherapy.

The company's proprietary Aster platform underpins Neutrocheck, enabling rapid analysis of a single finger-prick blood sample. This portable technology measures key biomarkers, offering a swift and user-friendly method for early detection of sepsis risk. This development is particularly significant given industry reports suggesting a substantial portion of hospital visits for neutropenic sepsis may be preventable, highlighting the potential for 52North's solution to alleviate strain on healthcare resources.

This latest financing, co-led by Macmillan Ventures and Hargreave Hale AIM VCT, marks a significant milestone for 52North. Macmillan Ventures, the recently established investment arm of Macmillan Cancer Support, is making its debut as a co-lead investor. Notably, Hargreave Hale AIM VCT contributed £1 million, representing the largest single investment from a new backer in the company's history. The round also benefited from a grant through Innovate UK’s Investor Partnerships programme, a government initiative designed to catalyze commercialization for high-potential UK enterprises.

With this new funding, 52North's total equity raised now surpasses £7.5 million. The strategic investment will primarily fuel further clinical trials, navigate the complex regulatory pathways, and support the initial market introduction of Neutrocheck within the United Kingdom. The company's mission to transform urgent cancer care is bolstered by the strong conviction of its investors.

Existing supporters reaffirming their commitment include Cedars Sinai Intellectual Property Company, Cancer Research Horizons, the University of Cambridge, and OKG Capital. The participation of these established entities alongside new strategic partners underscores the perceived value and transformative potential of 52North's technology in the oncology support sector. The healthtech market, particularly in diagnostics for critical conditions, continues to attract significant investment as providers seek more efficient and patient-centric solutions.

Umaima Ahmad, CEO and Co-founder of 52North, expressed enthusiasm for the round, stating, “This infusion of capital is a powerful endorsement of our platform and the dedicated team. We are focused on addressing critical gaps in healthcare with practical innovations. The involvement of Macmillan in its inaugural deal and Hargreave Hale’s substantial commitment highlight a shared vision to revolutionize cancer treatment support.” Felix Litzkow, Head of Macmillan Ventures, added that the platform’s potential to reduce patient anxiety and unnecessary hospitalizations aligns perfectly with their investment mandate. Anna Salim, Portfolio Manager at Hargreave Hale AIM VCT, commented on the company’s pivotal development stage and expressed delight in joining a robust syndicate of healthcare investors.